TransMedics Discloses Incentive Grants Under NASDAQ Regulation 5635(c)(4) for Equity Compensation
Massachusetts-based medical technology firm TransMedics Group, Inc. (Nasdaq: TMDX) has announced the granting of stock options and restricted stock units (RSUs) to 15 new employees, effective May 21, 2025. These incentives were a material inducement for each employee's entry into employment with the company.
The non-qualified stock options allow the purchase of 9,940 shares of TransMedics' common stock, at a price of $121.31 per share, which matches the closing price of the common stock on the Nasdaq Global Market on May 21, 2022. The stock options will vest over a period of four years, with 25% vesting annually, provided the employee remains in service with the company.
In addition to the stock options, 6,670 RSUs were also granted. Similar to the stock options, each RSU will vest annually, with 25% vesting each year over a four-year period, contingent on the employee's continued service.
The Compensation Committee of TransMedics' Board of Directors approved these grants, which were made in accordance with Nasdaq Listing Rule 5635(c)(4) and TransMedics Group, Inc. Inducement Plan.
TransMedics is a global leader in portable extracorporeal warm perfusion and the assessment of donor organs for transplantation. Based in Andover, Massachusetts, the company works to address the need for more and better organs for transplantation by developing technologies to preserve organ quality, assess organ viability, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
For investor inquiries, contact Brian Johnston at +1 332-895-3222 or [email protected].
SOURCE TransMedics Group, Inc.
PRNewswire
TransMedics grants stock options and RSUs to 15 employees as part of a compensation package for their new roles, as stipulated in NASDAQ Listing Rule 5635(c)(4)
- The cloud of uncertainty surrounding the future of TransMedics Group, Inc. may dissipate as the 15 new employees, who have been granted stock options and RSUs, are expected to bring fresh perspectives from the medical-conditions, health-and-wellness, finance, and business sectors to the Massachusetts-based firm.
- As TransMedics continues to revolutionize organ transplantation through their cutting-edge technology, the recent news of stock options and RSUs granted to their employees highlights the company's commitment to science and attracting top talent.
- In a move to bolster its organizational structure, TransMedics Group, Inc. has extended financial incentives to its new employees in the form of stock options and RSUs, strategically aligning with the field of business and finance while simultaneously focusing on the development of their medical technology.
(4)%20for%20Equity%20Compensation){kind=link}